Journal
EPILEPSIA
Volume 58, Issue 8, Pages E96-E100Publisher
WILEY
DOI: 10.1111/epi.13815
Keywords
Cannabidiol; Quality of life; Seizures; Pediatric; Epilepsy
Categories
Funding
- GW Pharmaceuticals
Ask authors/readers for more resources
Recent clinical trials indicate that cannabidiol (CBD) may reduce seizure frequency in pediatric patients with certain forms of treatment-resistant epilepsy. Many of these patients experience significant impairments in quality of life (QOL) in physical, mental, and social dimensions of health. In this study, we measured the caregiver-reported Quality of Life in Childhood Epilepsy (QOLCE) in a subset of patients enrolled in a prospective, open-label clinical study of CBD. Results from caregivers of 48 patients indicated an 8.2 +/- 9.9-point improvement in overall patient QOLCE (p < 0.001) following 12 weeks of CBD. Subscores with improvement included energy/fatigue, memory, control/helplessness, other cognitive functions, social interactions, behavior, and global QOL. These differences were not correlated to changes in seizure frequency or adverse events. The results suggest that CBD may have beneficial effects on patient QOL, distinct from its seizurereducing effects; however, further studies in placebo-controlled, double-blind trials are necessary to confirm this finding.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available